Supplementary information

Study protocol and statistical analysis plans for the placebo-controlled and LTE periods.Reporting SummaryADAS-Cog13 results in the placebo-controlled and LTE periods. Analysis was performed using a mixed model for repeated measures with data from the placebo-controlled and LTE periods. Analyses were two-sided at a 5% significance level. No adjustments were made for multiple comparisons.